The Chemours Company (CC)
Automate Your Wheel Strategy on CC
With Tiblio's Option Bot, you can configure your own wheel strategy including CC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CC
- Rev/Share 39.1244
- Book/Share 1.5908
- PB 9.6926
- Debt/Equity 1.0295
- CurrentRatio 1.6757
- ROIC 0.0268
- MktCap 2288882420.0
- FreeCF/Share -0.233
- PFCF -65.3966
- PE -5.4694
- Debt/Assets 0.0326
- DivYield 0.0441
- ROE -0.8089
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CC | Mizuho | Neutral | Outperform | -- | $19 | March 27, 2025 |
| Initiation | CC | Truist | -- | Buy | -- | $27 | Jan. 28, 2025 |
News
Chemours Enters Strategic Agreement With SRF to Boost Supply
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CC partners with SRF to expand global supply chain, boost operational flexibility and strengthen its high-value product mix.
Read More
Chemours Q2 Earnings & Revenues Beat Estimates on Higher Volumes
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
CC posts Q2 earnings and sales beat driven by volume and pricing gains, but issues softer sequential guidance.
Read More
Chemours: Solid Q2 And Legal Progress Are Bullish (Rating Upgrade)
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Positive
Chemours is showing financial improvement, especially in Opteon refrigerants, despite industry headwinds and a recent dividend cut. The company's legal overhang is easing after a favorable New Jersey PFAS settlement, freeing up future cash flow and reducing uncertainty. Balance sheet leverage remains high, but improving free cash flow in the second half should reduce net debt and support the current dividend.
Read More
The Chemours Company (CC) Q2 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
The Chemours Company (NYSE:CC ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Brandon Ontjes - Vice President of Investor Relations Denise M. Dignam - President, CEO & Director Shane W.
Read More
CC Sees Gains From Opteon Growth in Q2, Navigates Disruptions in TT
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Chemours' second-quarter sales are expected to be at the high end of its guidance as TT disruptions get offset by Opteon demand boosts.
Read More
Chemours & Navin Fluorine Partner to Produce Liquid Cooling Product
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
CC partners with Navin Fluorine to facilitate the adoption of two-phase liquid cooling.
Read More
Chemours' Q1 Earnings Miss Estimates, Revenues Increase Y/Y
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
CC's first-quarter earnings miss estimates, but revenues beat the same on increased sales from Titanium Technologies and Thermal & Specialized Solutions.
Read More
The Chemours Company (CC) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
The Chemours Company (NYSE:CC ) Q1 2025 Results Conference Call May 7, 2025 8:00 AM ET Company Participants Brandon Ontjes - VP, Investor Relations Denise Dignam - President & Chief Executive Officer Shane Hostetter - Chief Financial Officer Conference Call Participants John McNulty - BMO John Roberts - Mizuho Pete Osterland - Truist Laurence Alexander - Research Analyst Arun Viswanathan - RBC Capital Markets Josh Spector - UBS Duffy Fischer - Goldman Sachs Mike Leithead - Barclays Operator Good morning. My name is Michelle, and I will be your conference operator today.
Read More
Chemours: Dividend Cut May Signal A Bottom Is Near
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Negative
Chemours has faced significant challenges, including weak demand, excess supply, and poor earnings, leading to a 50% drop in stock value and a 9% after-hours plunge. Despite weak performance, Chemours is nearing a potential buy point due to its free cash flow generation and strategic dividend cut to safeguard its balance sheet. CC expects sequential sales growth and a 40-45% increase in adjusted EBITDA, but the outlook remains cautious due to economic uncertainties and tariffs.
Read More
Chemours (CC) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Chemours (CC) Q1 Earnings Miss Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Chemours (CC) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.32 per share a year ago.
Read More
Chemours and Navin Fluorine Announce Agreement to Manufacture New Liquid Cooling Product as a Part of Chemours Expanded Liquid Cooling Venture
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours and Navin Fluorine Announce Agreement to Manufacture New Liquid Cooling Product as a Part of Chemours Expanded Liquid Cooling Venture.
Read More
The Chemours Company Reports First Quarter 2025 Results
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--The Chemours Company Reports First Quarter 2025 Results.
Read More
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Chemours, NTT DATA & Hibiya Engineering Join Forces for Product Trial
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
CC partners with industry leaders to address the data center cooling gap by conducting Opteon 2P50 product trials.
Read More
The Long-Term Upside For Chemours Company After Q4 2024
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive
I've been investing in Chemours for years, despite recent accounting irregularities and share price decline since before 2024. Chemours, a leader in the titanium dioxide sector, also excels in new refrigerants like Opteon due to regulatory changes. Despite recent poor returns, I remain confident in Chemours' fundamentals and long-term potential, especially after 4Q24.
Read More
The Chemours Company Reports Fourth Quarter and Full Year 2024 Results
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--The Chemours Company Reports Fourth Quarter and Full Year 2024 Results.
Read More
Chemours Announces First Quarter Dividend
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Announces First Quarter Dividend.
Read More
Chemours Appoints Leslie M. Turner to its Board of Directors
Published: February 11, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Appoints Leslie M. Turner to its Board of Directors.
Read More
Earnings Preview: Chemours (CC) Q4 Earnings Expected to Decline
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
About The Chemours Company (CC)
- IPO Date 2015-06-19
- Website https://www.chemours.com
- Industry Chemicals - Specialty
- CEO Denise M. Dignam
- Employees 6000